LXRX Stock Summary and Trading Ideas (Lexicon Pharmaceuticals | NASDAQ:LXRX)

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Lexicon Pharmaceuticals trades on the NASDAQ stock market under the symbol LXRX.

As of February 5, 2026, LXRX stock price declined to $1.18 with 6,670,562 million shares trading.

LXRX has a beta of 2.28, meaning it tends to be more sensitive to market movements. LXRX has a correlation of 0.10 to the broad based SPY ETF.

LXRX has a market cap of $493.08 million. This is considered a Small Cap stock.

Last quarter Lexicon Pharmaceuticals reported $14 million in Revenue and -$.04 earnings per share. This beat revenue expectation by $9 million and exceeded earnings estimates by $.03.

In the last 3 years, LXRX traded as high as $3.79 and as low as $.28.

The top ETF exchange traded funds that LXRX belongs to (by Net Assets): VTI, VXF, SCHA, PRFZ, VHT.

LXRX has outperformed the market in the last year with a return of +55.2%, while the SPY ETF gained +13.8%. However, in the most recent history, LXRX shares have underperformed the stock market with its stock returning -11.3% in the last 3 month period and -24.4% for the last 2 week period, while SPY has returned +0.6% and -1.1%, respectively.

LXRX support price is $1.17 and resistance is $1.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LXRX shares will trade within this expected range on the day.